PURPOSE OF REVIEW: Bicuspid aortic valve stenosis is regarded as a relative contraindication for transcatheter aortic valve replacement (TAVR) according to current guidelines, as patients with bicuspid anatomy (BiAV) were excluded from landmark clinical trials.In this review, we will discuss the feasibilty, safety and outcomes of TAVR in BiAV, based upon the current literature and our own experience. RECENT FINDINGS: The currently available data come from observational registries with low sample size, and only in a few were the results of TAVR in BiAV compared with those achieved in the cohort with tricuspid anatomy. TAVR proved to be technically feasible in selected BiAV patients, and the mid-term clinical outcomes are acceptable. Nevertheless, there are still some unresolved issues, such as long-term valve durability and the relatively high rate of paravalvular leakage. SUMMARY: The existing literature supports the use of TAVR in selected high-risk BiAV patients, although the final role of this technique in this cohort of patients can only be established once a larger, preferably randomized, study comparing TAVR with surgery is performed.
PURPOSE OF REVIEW: Bicuspid aortic valve stenosis is regarded as a relative contraindication for transcatheter aortic valve replacement (TAVR) according to current guidelines, as patients with bicuspid anatomy (BiAV) were excluded from landmark clinical trials.In this review, we will discuss the feasibilty, safety and outcomes of TAVR in BiAV, based upon the current literature and our own experience. RECENT FINDINGS: The currently available data come from observational registries with low sample size, and only in a few were the results of TAVR in BiAV compared with those achieved in the cohort with tricuspid anatomy. TAVR proved to be technically feasible in selected BiAV patients, and the mid-term clinical outcomes are acceptable. Nevertheless, there are still some unresolved issues, such as long-term valve durability and the relatively high rate of paravalvular leakage. SUMMARY: The existing literature supports the use of TAVR in selected high-risk BiAV patients, although the final role of this technique in this cohort of patients can only be established once a larger, preferably randomized, study comparing TAVR with surgery is performed.
Authors: Tian-Yuan Xiong; Walid Ben Ali; Yuan Feng; Kentaro Hayashida; Hasan Jilaihawi; Azeem Latib; Michael Kang-Yin Lee; Martin B Leon; Raj R Makkar; Thomas Modine; Christoph Naber; Yong Peng; Nicolo Piazza; Michael J Reardon; Simon Redwood; Ashok Seth; Lars Sondergaard; Edgar Tay; Didier Tchetche; Wei-Hsian Yin; Mao Chen; Bernard Prendergast; Darren Mylotte Journal: Nat Rev Cardiol Date: 2022-06-20 Impact factor: 32.419
Authors: Aleksandra Gasecka; Michał Walczewski; Adam Witkowski; Maciej Dabrowski; Zenon Huczek; Radosław Wilimski; Andrzej Ochała; Radosław Parma; Piotr Scisło; Bartosz Rymuza; Karol Zbroński; Piotr Szwed; Marek Grygier; Anna Olasińska-Wiśniewska; Dariusz Jagielak; Radosław Targoński; Grzegorz Opolski; Janusz Kochman Journal: Front Cardiovasc Med Date: 2022-06-21
Authors: Janusz Kochman; Karol Zbroński; Łukasz Kołtowski; Radosław Parma; Andrzej Ochała; Zenon Huczek; Bartosz Rymuza; Radosław Wilimski; Maciej Dąbrowski; Adam Witkowski; Piotr Scisło; Marek Grygier; Maciej Lesiak; Grzegorz Opolski Journal: Clin Res Cardiol Date: 2019-09-02 Impact factor: 5.460
Authors: Piotr A Chodór; Krzysztof Wilczek; Karolina Chodór-Rozwadowska; Roman Przybylski; Jan Głowacki; Tomasz Niklewski; Łukasz Włoch; Mariusz Gąsior; Marian Zembala; Zbigniew Kalarus Journal: Postepy Kardiol Interwencyjnej Date: 2021-03-27 Impact factor: 1.426
Authors: Xin Meng; Yandan Sun; Wei Bai; Yuxi Li; Shengjun Tuo; Liang Cao; Mengmeng Du; Yang Liu; Ping Jin; Jian Yang; Liwen Liu Journal: Ann Transl Med Date: 2022-01